好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Tandem gait step-width declines more rapidly in a stage-dependent manner with Parkinson’s disease progression
Movement Disorders
P2 - Poster Session 2 (11:45 AM-12:45 PM)
5-007
To determine if tandem gait progression is dependent on disease severity in Parkinson’s disease.

Tandem gait is widely used to assess a variety of neurologic and vestibular diseases. Tandem gait has been reported to predict fall risk in idiopathic Parkinson’s disease (PD) and help distinguish it from other forms of parkinsonism. We previously showed that tandem gait step-width widens with increasing Hoehn and Yahr (H&Y) disease severity. The change in specific tandem gait parameters in PD patients over time could contribute to understanding the pathology of the disease.

Tandem gait was collected using an instrumented gait mat in 50 PD participants and 21 controls at six-month intervals over a period of at least 24 months. The PD participants were further grouped based on their H&Y staging into stage 1, stage 2, or stage ≥ 2.5. The mean of the tandem gait variables step-width, step-length, step-time, and step-velocity were determined at each visit and the annual percent change in each variable for each participant over time was calculated. A student’s t-test was used to compare groups.

Compared to controls (1.44±2.18), the mean rate of increase of step-width was found to be significantly faster in H&Y stage 2 participants (11.47±4.35, p=0.04) and H&Y stage 2.5+ participants (15.97±5.47, p=0.03), but not in H&Y stage 1 participants (6.43±7.00, p=0.5). No significant difference in progression was found between controls and any H&Y group for the other 3 variables.

Step-width in tandem gait increases at a faster rate in a PD stage-dependent manner, and adds to the growing evidence that cerebellar pathways contribute to the pathology of PD. These results suggest that tandem gait should be evaluated in PD patients in the clinic setting and should be taken into consideration when managing imbalance in PD. 
Authors/Disclosures
Jennie Burns, MD
PRESENTER
Dr. Burns has nothing to disclose.
Lakshmi Pillai (University of Arkansas for Medical Sciences Little RoCK) Ms. Pillai has nothing to disclose.
Aliyah J. Glover (UAMS Neurology) Miss Glover has nothing to disclose.
Tuhin Virmani, MD, PhD, FAAN (University of Arkansas for Medical Sciences) The institution of Dr. Virmani has received research support from Parkinson's Foundation.